9 completed, 1 active not recruiting, 1 enrolling by invitation, 1 terminated. 9 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow eteplirsen: new trials by email Literature Review of eteplirsen trials Research Report on eteplirsen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) Eteplirsen - Muscular Dystrophy, Duchenne | Phase 3 | Active not recruiting | Sarepta Therapeutics, Inc. | 160 | 2020-07-13 | 2026-02-27 |
| A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications. Amondys 45, Exondys 51, Vyondys 53 - Duchenne Muscular Dystrophy | Phase 2 | Completed | Kevin Flanigan | 3 | 2020-02-18 | 2023-10-26 |
| A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995) Eteplirsen - Duchenne Muscular Dystrophy | Phase 2 | Terminated | Sarepta Therapeutics, Inc. | 15 | 2019-06-26 | 2023-08-18 |
| A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice Eteplirsen, Golodirsen, Casimersen - Duchenne Muscular Dystrophy | Enrolling by invitation | Sarepta Therapeutics, Inc. | 300 | 2019-01-07 | 2025-09-10 | |
| Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping Eteplirsen - Duchenne Muscular Dystrophy | Phase 2 | Completed | Sarepta Therapeutics, Inc. | 15 | 2017-08-16 | 2021-12-09 |
| Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy eteplirsen - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Completed | Sarepta Therapeutics, Inc. | 33 | 2015-06-30 | 2021-01-25 |
| Study of Eteplirsen in DMD Patients eteplirsen - Duchenne Muscular Dystrophy (DMD) | Phase 3 | Completed | Sarepta Therapeutics, Inc. | 109 | 2014-11-17 | 2021-01-25 |
| Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy Eteplirsen - Muscular Dystrophy, Duchenne | Phase 2 | Completed | Sarepta Therapeutics, Inc. | 24 | 2014-11-01 | 2020-03-30 |
| Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy AVI-4658 (Eteplirsen) - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Completed | Sarepta Therapeutics, Inc. | 12 | 2012-02-27 | 2020-03-30 |
| Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients AVI-4658 (Eteplirsen), Placebo - Duchenne Muscular Dystrophy | Phase 2 | Completed | Sarepta Therapeutics, Inc. | 12 | 2011-07-01 | 2020-03-30 |
| Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients AVI-4658 for Injection - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Completed | Sarepta Therapeutics, Inc. | 19 | 2009-01-01 | 2015-10-06 |
| Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy AVI-4658 (PMO) - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Completed | Imperial College London | 7 | 2007-10-26 | 2019-12-05 |
Muscular Dystrophy, Duchenne (12)
Sarepta Therapeutics, Inc. (10) · Imperial College London (1) · Kevin Flanigan (1)
United States (8) · United Kingdom (5) · France (3) · Italy (3) · Belgium (2) · Colombia (1) · Czechia (1) · Denmark (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Ireland (1) · Jordan (1) · Mexico (1)
Austen Eddy, MSM (1) · Francesco Muntoni, FRCPCH (1) · Kate Bushby, MRCP (1) · Kevin Flanigan, MD (1) · Volker Straub, FRCPCH (1)
PMID 26573217, PMID 19713152, PMID 21784508, PMID 23907995, PMID 37207382, PMID 41961051
2018 (1), 2019 (1)